Plain-English translation of NCT04649242 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called rimegepant to see if it can quickly relieve moderate to severe migraine headaches in children and teenagers. About 2,100 young people will participate, and half will receive the active medication while the other half receive a placebo (a pill with no active ingredient) to fairly compare how well the treatment works. Researchers want to understand both whether this medication is effective at stopping migraines and whether it is safe for young patients to use.
While migraine affects many children and teenagers, there are limited treatment options specifically approved and studied for this age group. This trial aims to fill that gap by providing evidence that this medication can safely and effectively stop migraine attacks in young people.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the active medication or a placebo as a dissolving tablet when you have a migraine attack. You'll need to attend a screening visit first to confirm you qualify, and then you'll take part in the treatment phase where you'll use your assigned medication during migraine episodes and report how well it works. The study team will monitor your safety and wellbeing throughout the trial with follow-up visits and will ask you questions about your migraines and any side effects you experience.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States